Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone and gemcitabine in advanced pancreatic cancer
NCT05795920Phase 2Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in pancreatic cancer (PC), sponsored by Shanghai General Hospital. Primary endpoints: Overall Survival at 100 months and Progression-Free Survival at 100 months. Status: unknown.
02
Drugs
utidelone
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05795920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795920.